论文部分内容阅读
目的探讨肺心病患者血浆CGRP,ET-1水平与PA I-1基因4G/5G多态性的相关性。方法用放免法测定正常组与肺心病组血浆CGRP,ET-1水平;PCR技术检测肺心病PA I-1基因4G/5G多态性的基因型,并分析不同式因型血浆CGRP,ET-1的水平。结果肺心病组和正常对照组血浆ET-1含量分别为77.4±13.1ng l/L和52.2±15.6ng/L,差异有显著性(P<0.01)。肺心病组和正常对照组CGRP血浆含量分别为23.6±14.4ng/L和48.3±17.5ng/L,两者间具有显著性差异(P<0.01)。4G/4G基因型肺心病患者血浆ET-1水平明显高于4G/5G和5G/5G基因型肺心病患者(P<0.05)。结论肺心病患者血冰岛CGRP水平与ET-1水平呈负相关,共同参与肺心病病理过程的调节;4G/4G多态性能影响ET-1的活性,二者在肺心病发生发展中具有协同作用。而CGRP与4G/5G多态性无相关性。
Objective To investigate the correlation between plasma CGRP and ET-1 levels and PA I-1 4G / 5G polymorphism in patients with cor pulmonale. Methods Plasma CGRP and ET-1 levels were measured by radioimmunoassay (RIA) in normal and pulmonary heart disease groups. Genotypes of 4G / 5G polymorphism of PA I-1 gene in patients with pulmonary heart disease were detected by PCR and the plasma levels of CGRP and ET- 1 level. Results The plasma levels of ET-1 in pulmonary heart disease group and normal control group were 77.4 ± 13.1ng l / L and 52.2 ± 15.6ng / L, respectively (P <0.01). Plasma levels of CGRP in pulmonary heart disease group and normal control group were 23.6 ± 14.4ng / L and 48.3 ± 17.5ng / L, respectively, with significant difference (P <0.01). Plasma ET-1 levels in patients with 4G / 4G genotype were significantly higher than those with 4G / 5G and 5G / 5G genotypes (P <0.05). Conclusions The level of CGRP in Icelandic blood is negatively correlated with the level of ET-1 in patients with cor pulmonale, which may play a role in the pathogenesis of pulmonary heart disease. The 4G / 4G polymorphism may affect the activity of ET-1, which may have synergistic effects on the development of pulmonary heart disease . The CGRP and 4G / 5G polymorphism no correlation.